ArticleJournal of Cancer2026
Mutation Patterns Define Clinical Heterogeneity in Acute Myeloid Leukemia.
Article in Journal of Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute myeloid leukemia (AML) is a molecularly heterogeneous malignancy where next-generation sequencing (NGS) has revolutionized risk stratification and treatment paradigms. However, the interplay between mutation cooperativity, clinical phenotypes, and biochemical markers of organ dysfunction remains poorly characterized. This study investigates how co-mutational patterns influence hematological/biochemical parameters and survival outcomes in AML. Methods: In this single-center retrospective study (2017-2024), 1,416 non-M3 AML patients with NGS-confirmed somatic mutations were analyzed. Clinical parameters included hematologic parameters, biochemical markers, and survival outcomes. Multivariate Cox models, Kaplan-Meier analysis, propensity score matching (1:4), and Cohen's d effect sizes were employed to assess mutation-clinical correlations. Results: A higher mutational burden was associated with older age, elevated platelets, and renal impairment, with Conclusions: These findings support integrating genomic and biochemical profiling for AML management, as co-mutation patterns, particularly those affecting renal function, refine risk stratification and highlight the need for tailored monitoring and organ support.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.